Spyre Therapeutics, Inc. — FY 2023 Form 10-K Summary
Business context and reporting period
Spyre Therapeutics, formerly Aeglea BioTherapeutics, reported results for the fiscal year ended December 31, 2023. The company completed its acquisition of Pre-Merger Spyre on June 22, 2023, changed its name in November 2023, and repositioned itself as a preclinical biotechnology company focused on inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease.
The pipeline is centered on long-acting monoclonal antibodies and potential combination therapies. SPY001, an anti-α4β7 antibody, and SPY002, an anti-TL1A antibody, are the lead programs. All programs remained preclinical at year-end, and no product candidate had been tested in humans or approved for commercialization.
Financial performance and key metrics
| Metric | FY 2023 | FY 2022 | Change |
|---|---|---|---|
| Total revenue | $0.9 million | $2.3 million | Down 62% |
| Research and development expense | $89.5 million | $58.6 million | Up 53% |
| General and administrative expense | $39.9 million | $28.5 million | Up 40% |
| Acquired in-process R&D expense | $130.2 million | — | Nonrecurring acquisition item |
| Gain on sale of in-process R&D | $16.4 million | — | Related to pegzilarginase sale |
| Net loss | $338.8 million | $83.8 million | Loss increased materially |
| Basic and diluted loss per share | $49.12 | $24.86 | Loss per share increased |
| Net cash used in operating activities | $99.9 million | $80.1 million | Use increased |
| Cash, cash equivalents and marketable securities | $339.3 million | $55.7 million | Substantially increased |
Revenue consisted of $0.9 million from the legacy Immedica agreement for pegzilarginase-related development services, drug supply and royalties. The company generated no commercial product revenue and expects no product sales revenue for the foreseeable future.
The net loss included significant non-cash and unusual items, including $130.2 million of acquired in-process R&D, an $83.5 million change in the fair value of a forward contract liability related to Series A preferred stock, $19.0 million of CVR liability remeasurement expense, and $25.7 million of stock-based compensation.
At December 31, 2023, total assets were $341.9 million, total liabilities were $73.3 million, and accumulated deficit was $764.4 million. The filing does not identify material conventional debt outstanding at year-end. However, Series B preferred stock with a carrying value of $84.6 million was classified outside stockholders’ equity because it may become cash-redeemable if stockholder approval for conversion is not obtained.
Material changes versus the prior comparable period
- The company transitioned from a legacy rare-disease business to an IBD-focused preclinical platform following the Pre-Merger Spyre acquisition.
- Research and development spending increased by $30.9 million, primarily from IBD pipeline development and manufacturing activities, partly offset by lower legacy-program costs.
- External R&D costs increased to $72.7 million from $36.4 million, including $48.5 million of expenses related to Paragon services after the acquisition. Related-party liabilities owed to Paragon totaled $16.6 million at year-end.
- General and administrative expense increased by $11.4 million, reflecting higher stock compensation, restructuring costs, and legal and professional fees.
- The company recognized a $16.4 million gain from selling global pegzilarginase rights to Immedica for $15.0 million upfront cash plus potential contingent milestone payments of up to $100.0 million.
- The company raised approximately $390.0 million in gross proceeds through the June 2023 Series A preferred stock financing and the December 2023 common stock and Series B preferred stock financing.
- Cash flows from investing activities shifted to a $108.4 million use, largely because of purchases of marketable securities, while financing cash flow increased to $361.1 million.
- An April 2023 restructuring reduced headcount by approximately 83% by June 30, 2023. Total restructuring costs were $11.0 million, including $6.4 million of severance-related costs and $2.6 million of lease and leasehold impairment.
Guidance, outlook, commentary, risks and contingencies
- Management expects to submit an IND or equivalent foreign filing and begin a Phase 1 study of SPY001 in the first half of 2024, with interim data expected by year-end 2024, subject to regulatory approval.
- Management expects to submit an IND or equivalent filing and begin a Phase 1 study of SPY002 in the second half of 2024, with interim data expected in the first half of 2025, subject to additional data and regulatory approval.
- SPY003 is a discovery-stage anti-IL-23 program; a development candidate was expected to be nominated in mid-2024, with IND-enabling work expected to begin in the second half of 2024.
- The company plans preclinical combination studies, including SPY120, and anticipates clinical combination studies in 2025, subject to regulatory clearance.
- Management stated that existing cash, cash equivalents and marketable securities are expected to fund operations for at least one year from the issuance date of the financial statements. Additional financing will be required to fund later-stage research, clinical development and potential commercialization.
- The company remains dependent on third parties, including Paragon and contract manufacturers such as WuXi Biologics. Supply-chain, geopolitical and potential BIOSECURE-related restrictions could affect manufacturing and clinical timelines.
- Following execution of the SPY001 and SPY002 license agreements, Spyre expects to owe Paragon up to $22.0 million per program in development, regulatory and clinical milestones, plus a $1.5 million development-candidate nomination fee and a $2.5 million first-patient-dosing payment for each applicable program. These obligations were not accrued at year-end because the definitive license agreements were still being finalized.
- The company’s $42.7 million CVR liability is based on Level 3 assumptions, including regulatory probabilities, reimbursement rates and discount rates. Future CVR payments depend on legacy-asset monetization and regulatory or reimbursement events.
- Stockholder approval is required for conversion of the 150,000 outstanding Series B preferred shares into 6.0 million common shares. If approval is not obtained, holders may have the right to require cash settlement; the filing provides an illustrative potential cash settlement of $141.5 million based on a February 2024 stock price.
- Key risks include clinical and regulatory failure, inability to translate non-human-primate half-life results to humans, adverse events, manufacturing and supply disruption, dependence on Paragon, intellectual-property challenges, dilution from future financing, and stock-price volatility.
Most important facts for investors to verify
- Whether SPY001 and SPY002 IND filings were submitted and accepted, and whether Phase 1 trials began on the stated timelines.
- Human safety, pharmacokinetic and half-life data for SPY001 and SPY002, particularly whether preclinical dosing advantages translate to humans.
- Actual cash burn, updated cash runway and the timing and terms of future equity or debt financing.
- Outcome of the Series B conversion vote and any resulting cash-redemption obligation or dilution.
- Execution and final terms of the SPY001 and SPY002 license agreements with Paragon, including milestone and related-party payment obligations.
- Status of the pegzilarginase regulatory and reimbursement milestones and the amount, timing and distribution of any CVR proceeds.
- Manufacturing readiness, supply-chain diversification and exposure to WuXi Biologics or related regulatory restrictions.
- Changes in the competitive IBD landscape, including competing TL1A, IL-23 and α4β7 programs.